{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:08:35Z","timestamp":1758046115810,"version":"3.44.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.ando.2008.02.015","type":"journal-article","created":{"date-parts":[[2008,4,19]],"date-time":"2008-04-19T09:07:36Z","timestamp":1208596056000},"page":"147-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["New treatments of diabetes: The \u03b2-amylin agonists"],"prefix":"10.1016","volume":"69","author":[{"given":"H.E.","family":"Lebovitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2008.02.015_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1054-3589(05)52001-5","article-title":"Amylin physiology and pharmacology","volume":"52","author":"Young","year":"2005","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.ando.2008.02.015_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-291X(91)91325-7","article-title":"Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretogogues, islet hormones and hypoglycemic agents","volume":"179","author":"Moore","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ando.2008.02.015_bib3","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","article-title":"Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients","volume":"84","author":"Cooper","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ando.2008.02.015_bib4","first-page":"977","article-title":"Localization of the amylin locus to chromosome 12 (Abstract)","volume":"51","author":"Cockburn","year":"1989","journal-title":"Cytogenet Cell Genet"},{"key":"10.1016\/j.ando.2008.02.015_bib5","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1210\/endo.140.6.6930","article-title":"An amylin receptor is revealed following cotransfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3","volume":"140","author":"Muff","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.ando.2008.02.015_bib6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1042\/BST0320865","article-title":"Amylin receptors: molecular composition and pharmacology","volume":"32","author":"Hay","year":"2004","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.ando.2008.02.015_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/014572179902500310","article-title":"Clinical implications of amylin and amylin deficiency","volume":"25","author":"Kruger","year":"1999","journal-title":"Diabetes Educ"},{"key":"10.1016\/j.ando.2008.02.015_bib8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0026-895X(25)13212-4","article-title":"High affinity amylin binding sites in rat brain","volume":"44","author":"Beaumont","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ando.2008.02.015_bib9","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1152\/ajpregu.00333.2003","article-title":"The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis","volume":"286","author":"Riediger","year":"2004","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.ando.2008.02.015_bib10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0167-0115(97)01034-3","article-title":"Comparison of Fos induced in rat brain by GLP-1 and amylin","volume":"71","author":"Rowland","year":"1997","journal-title":"Regul Pept"},{"key":"10.1016\/j.ando.2008.02.015_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0196-9781(97)00292-1","article-title":"Lesion of the area postrema\/nucleus of the solitary tract (AP\/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats","volume":"19","author":"Lutz","year":"1998","journal-title":"Peptides"},{"key":"10.1016\/j.ando.2008.02.015_bib12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.ijo.0801664","article-title":"The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema\/nucleus of the solitary tract (AP\/NTS) lesioned rats","volume":"25","author":"Lutz","year":"2001","journal-title":"Int J Obeselat Metab Disord"},{"key":"10.1016\/j.ando.2008.02.015_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M","article-title":"Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin","volume":"37","author":"Young","year":"1996","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.ando.2008.02.015_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/j.1552-4604.1996.tb04147.x","article-title":"Pharmacokinetics and pharmacodynamics of AC 137 (25,28,29 tripro amylin, human) after intravenous bolus and infusion doses in patients with insulin dependent diabetes","volume":"36","author":"Colburn","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ando.2008.02.015_bib15","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ando.2008.02.015_bib16","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/oby.2007.626","article-title":"Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects","volume":"15","author":"Chapman","year":"2007","journal-title":"Obesity"},{"key":"10.1016\/j.ando.2008.02.015_bib17","first-page":"235A","article-title":"Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve (abstract)","volume":"45","author":"Jodka","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2008.02.015_bib18","first-page":"2220","article-title":"Relalationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus","volume":"36","author":"Jones","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ando.2008.02.015_bib19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/BF00400362","article-title":"Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects","volume":"36","author":"Horowitz","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2008.02.015_bib20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/0016-5085(88)90248-X","article-title":"Serum glucose concentration as a modulator of interdigestive gastric motility","volume":"94","author":"Barnett","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ando.2008.02.015_bib21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s001250050949","article-title":"The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM","volume":"41","author":"Kong","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2008.02.015_bib22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s001250050646","article-title":"Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM","volume":"40","author":"Kong","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2008.02.015_bib23","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-2002-34790","article-title":"The human analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes","volume":"34","author":"Fineman","year":"2002","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.ando.2008.02.015_bib24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/meta.2002.32022","article-title":"The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes","volume":"51","author":"Fineman","year":"2002","journal-title":"Metabolism"},{"issue":"2 Pt 1","key":"10.1016\/j.ando.2008.02.015_bib25","first-page":"E283","article-title":"Impact of lack of suppression of glucagon on glucose tolerance in humans","volume":"277","author":"Shah","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ando.2008.02.015_bib26","first-page":"1083","article-title":"Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus","volume":"81","author":"Nyholm","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2008.02.015_bib27","doi-asserted-by":"crossref","first-page":"E620","DOI":"10.1152\/ajpendo.00217.2007","article-title":"Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study","volume":"293","author":"Smith","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ando.2008.02.015_bib28","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.2337\/diacare.26.11.3074","article-title":"Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study","volume":"26","author":"Weyer","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2008.02.015_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.26.1.1","article-title":"Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated withinsulin pumps","volume":"26","author":"Levetan","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2008.02.015_bib30","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2008.02.015_bib31","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.ando.2008.02.015_bib32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2337\/dc06-1026","article-title":"Effect of adjunctive pramlintide treatment in treatment satisfaction in patients with type 1 diabetes","volume":"30","author":"Marrero","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2008.02.015_bib33","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2008.02.015_bib34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive therapy with t he amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated patients with type 2 diabetes","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.ando.2008.02.015_bib35","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.2337\/dc07-0589","article-title":"Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin","volume":"30","author":"Riddle","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2008.02.015_bib36","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","article-title":"A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes","volume":"29","author":"Edelman","year":"2006","journal-title":"Diabetes Care"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426608000498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426608000498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:42:48Z","timestamp":1757716968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426608000498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0003426608000498"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2008.02.015","relation":{},"ISSN":["0003-4266"],"issn-type":[{"type":"print","value":"0003-4266"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New treatments of diabetes: The \u03b2-amylin agonists","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2008.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}